Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Neoadjuvant Chemoimmunotherapy in Locally Advanced Cervical Cancer
NCT06288373Phase 3Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2024
- Primary completion
- Mar 2031
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Cervical Cancer (CC), sponsored by Tongji Hospital. Started Apr 2024; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06288373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06288373.